gdc
ImmunotherapyLung Cancer

Immune Checkpoint Inhibitors Offer New Hope for Patients with Lung Cancer

Several immune checkpoint inhibitors are now approved for patients with non–small-cell lung cancer, giving hope to patients living with this disease.
November 2018 Volume 4 – Lung Cancer
Jane Morgan

Lung cancer remains the leading cause of cancer-related deaths in men and women, accounting for 1 in every 4 deaths caused by cancer in the United States. However, recent advances in immunotherapy, especially those called “immune checkpoint inhibitors,” bring new hope for patients with lung cancer.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLung Cancer
Libtayo Approved for First-Line Treatment of Advanced Lung Cancer
The immunotherapy Libtayo received FDA approval as the first treatment option for patients with advanced or metastatic non–small-cell lung cancer and high PD-L1 expression.
Lung Cancer
Exposure to Occupational Toxins Increases the Risk for Lung Cancer
By Treven Pyles
Learning about lung cancer risks is important. An issue that needs more awareness is occupational exposure to harmful chemicals and the negative effects such exposure has on our health.
Patient StoriesLung Cancer
A Walking Miracle: My Cancer Journey
By Veronica Brent
When Veronica Brent had a constant cough and shortness of breath from walking, her daughter suggested she should have a chest x-ray. The x-ray showed she had lung cancer, and a biopsy showed she had cancer on the pancreas. She was concerned how to break the news to the family.
Lung CancerFDA Approvals, News & Updates
FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the second MET inhibitor that has been approved by the FDA.
Last modified: June 22, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country